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Inflammatory Skin Disease in K5.hTGF-b1 Transgenic
Mice Is Not Dependent on the IL-23/Th17
Inflammatory Pathway
Erin L. Fitch1,2, Heather L. Rizzo1, Stephen E. Kurtz3, Keith W. Wegmann4, Wei Gao5,
Jacqueline M. Benson5, David J. Hinrichs4 and Andrew Blauvelt1,2,3
In the presence of IL-6, transforming growth factor (TGF)-b1 induces differentiation of T helper (Th) 17 cells in
mice. Interleukin (IL)-23, a heterodimeric cytokine composed of IL-23p19 and IL-12/23p40 subunits, stimulates
the growth and expansion of Th17 cells, and has been implicated in psoriasis pathogenesis. To study the
associations between TGF-b1, the IL-23/Th17 inflammatory pathway, and psoriasis, we investigated inflammatory
skin disease in transgenic mice that constitutively overexpress human TGF-b1 in basal keratinocytes (K5.hTGF-b1
transgenic mice); these mice had previously been reported as having a psoriasis-like disease. K5.hTGF-b1
transgenic mice had high levels of TGF-b1 mRNA and protein in both skin and serum. Levels of cytokines
involved in IL-23/Th17-mediated inflammation were not elevated in lesional skin compared with those in non-
lesional and wild-type skin. It is noteworthy that IL-4 and IgE were markedly elevated in inflamed skin and
serum, respectively, of transgenic mice. Monoclonal antibodies (mAbs) specifically directed against IL-23p19 or
IL-12/23p40 had no clinical effect on established inflammatory skin disease in K5.hTGF-b1 transgenic mice,
whereas the same mAbs were able to block the development of murine experimental autoimmune
encephalomyelitis, an IL-23/Th17-mediated disease. In summary, the IL-23/Th17 inflammatory pathway is not
responsible for the maintenance of inflammatory skin disease in K5.hTGF-b1 transgenic mice.
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INTRODUCTION
Interleukin (IL)-23 is primarily produced by dendritic cells
(Oppmann et al., 2000), and is clearly elevated in psoriasis
lesions, as indicated by increased levels of mRNA for each of
its subunit components, IL-23p19 and IL-12/23p40, in
lesional skin as compared with those in non-lesional skin,
whereas mRNA levels of IL-12/35p35 are not elevated (Lee
et al., 2004; Chamian et al., 2005; Chan et al., 2006; Toichi
et al., 2006). Furthermore, an intradermal injection of
recombinant IL-23, but not of IL-12, into mice induces acute
histological changes reminiscent of human psoriasis (Chan
et al., 2006; Zheng et al., 2007). These IL-23-triggered
changes are dependent on cytokines produced by T helper
(Th) 17 cells (Zheng et al., 2007). Th17 cells are a newly
appreciated subset of CD4þ T helper cells, distinct from Th1
and Th2 cells, which are dependent on IL-23 for survival and
expansion (Oppmann et al., 2000; Aggarwal et al., 2003).
Genetic or antibody targeting of either IL-23 or Th17 cells
ameliorates several T-cell-mediated autoimmune disorders in
mice, including classic models of rheumatoid arthritis and
multiple sclerosis (Cua et al., 2003; Murphy et al., 2003;
Langrish et al., 2005; Chen et al., 2006). In contrast, targeting
of IL-12 or Th1 cells leads to worsening of these same
conditions (Cua et al., 2003; Murphy et al., 2003; Langrish
et al., 2005; Chen et al., 2006). Thus, the IL-23/Th17
inflammatory pathway is critical in mediating distinct
autoimmune T-cell-mediated inflammatory diseases in mice,
and its role in mediating inflammation in human psoriasis
appears to be equally important (Fitch et al., 2007).
Although IL-23 stimulates Th17 survival and proliferation,
differentiation of murine Th17 cells from naive T-cell
precursors is dependent on transforming growth factor
(TGF)-b1 in combination with IL-6 (Bettelli et al., 2006;
Mangan et al., 2006; Veldhoen et al., 2006). Neutralization
of TGF-b1 abrogates differentiation of naive murine CD4þ T
cells to Th17 cells in culture, whereas exposure to TGF-b1
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and pro-inflammatory cytokines, such as IL-6 induces Th0
cells to become mature Th17 effector cells (Veldhoen et al.,
2006). Mice that completely lack TGF-b1 have lower serum
levels of IL-17 and produce fewer IL-17þCD4þ splenic T
cells, whereas mice that overexpress TGF-b1 under the IL-2
promoter produce more antigen-stimulated IL-17 (Mangan
et al., 2006). In addition, TGF-b1 expression by T cells is
required for the induction of Th17 cells in certain tissues
(Li et al., 2007).
K5.hTGF-b1 transgenic mice overexpress latent human
TGF-b1 in basal keratinocytes and hair follicles under the K5
promoter, which leads to the development of inflammatory
skin disease (Li et al., 2004). A recent evaluation of murine
models of human psoriasis ranked K5.hTGF-b1 transgenic
mice high among the numerous models, because of clinical,
histological, and cellular similarities to human psoriasis
(Gudjonsson et al., 2007). These mice clinically showed
many clinical and cellular hallmarks of psoriasis, including
erythematous scaly plaques, epidermal hyperproliferation,
hyperkeratosis, acanthosis, and inflammatory cell infiltrates
of CD8þ T cells and neutrophils in the epidermis, and
CD4þ T cells and macrophages in the dermis (Li et al.,
2004). Clinical disease is apparent by 4 months of age in most
mice, with consistent Koebnerization of ears at sites of ear
tagging (Li et al., 2004). As TGF-b1 induces Th17 differentia-
tion in mice, and given the importance of Th17 cells in
human psoriasis, we investigated the role of the IL-23/Th17
inflammatory pathway in the pathogenesis of inflammatory
skin disease in K5.hTGF-b1 transgenic mice.
RESULTS
mRNA levels of IL-23/Th17 pathway cytokines are not elevated
in the lesional skin of K5.hTGF-b1 transgenic mice
To test the hypothesis that inflammatory skin disease in
K5.hTGF-b1 transgenic mice is because of the increased
presence of Th17 cells, we measured mRNA levels of several
cytokines that are important in the IL-23/Th17 inflammatory
pathway, using quantitative real-time reverse transcriptase
polymerase chain reaction (qRT-PCR) (Figure 1). Data are
expressed in three separate ways: comparison of lesional skin
with wild-type (WT) skin (Figure 1a); comparison of clinically
normal-appearing (that is, non-lesional) skin with WT
skin (Figure 1b); and comparison of lesional skin with non-
lesional skin (Figure 1c). As expected, lesional and non-
lesional skin contained high levels of hTGF-b1 mRNA. TNF-
a, IL-6, and IL-17A mRNAs were also elevated in lesional
skin. However, mRNAs specific for the IL-23p19 and IL-12/
23p40 subunits of IL-23, as well as for IL-23R, a component
of the IL-23 receptor expressed on Th17 cells, were present at
similar levels in both lesional and non-lesional skin as those
in WT skin. mRNA encoding the Th17 cell-associated
transcription factor, RORgt, was present at decreased levels
compared with that in WT skin. mRNA encoding IL-22, a key
Th17 effector cytokine, was not detected in any skin sample.
We next examined cytokines associated with Th1, Th2,
and regulatory T-cell (Treg) responses using qRT-PCR
(Figure 1). IL-12/35p35 levels were similar in both lesional
and WT skins. It is interesting that levels of IL-4, a Th2
cytokine, were high in transgenic lesional skin compared
with those in WT skin. Compared with non-lesional skin,
lesional skin had elevated mRNA levels for Treg-associated
cytokines, including foxp3, IL-10, and IL-12p35, which is a
component of IL-12 and of a newly described and crucial
Treg cytokine, IL-35 (Collison et al., 2007).
IL-23/Th17 cytokine protein levels are not detectable in lesional
skin of K5.hTGF-b1 transgenic mice
We isolated total protein from lesional and non-lesional skin
of K5.hTGF-b1 transgenic mice and analyzed tissue and
serum samples for the presence of IL-23 and Th17-related
cytokines by enzyme-linked immunosorbent assay (ELISA)
(Figure 2). Transgenic mice exhibited high levels of total
hTGF-b1 protein (Figure 2a). IL-1a protein was detected at
similar levels in skin obtained from both K5.hTGF-b1
transgenic mice and WT mice (data not shown). Protein
levels of IFN-g were slightly elevated and IL-4 levels were
markedly elevated in lesional skin (Figure 2b and c). As a
result of the latter finding, we tested the serum of transgenic
mice, and found serum IgE to be very high in K5.hTGF-b1
transgenic mice compared with that in WT mice (Figure 2d).
In contrast, IL-17A, IL-22, and IL-23 proteins were not
detected in skin of K5.hTGF-b1 transgenic mice or in that of
WT mice. WT and transgenic lymph node cultures treated
with IL-17-promoting cytokines showed high levels of IL-17A,
IL-22, and IL-12/23p40. IL-12/23p40 was also detected in
sera of both groups of mice. No differences were observed in
IL-17A, IL-22, and IL-12/23p40 protein levels in the lymph
node and sera between WT and K5.hTGF-b1 transgenic mice
(Figure 2e and h).
Treatment with neutralizing antibodies directed against IL-23
subunits, IL-23p19 or IL-12/23p40, does not improve
established inflammatory skin disease in K5.hTGF-b1 transgenic
mice
To determine the functional role of the IL-23/Th17 axis in
mice with advanced skin disease, we neutralized specific
components of the pathway with monoclonal antibodies
(mAbs), as has been done recently in humans with psoriasis
(Krueger et al., 2007; Kimball et al., 2008; Leonardi et al.,
2008; Papp et al., 2008). Treated mice were evaluated with a
clinical disease-scoring system to determine the response to
therapy. Mice with baseline disease scores of two or more
were treated for 3 weeks by intraperitoneal injection, with
1mg of neutralizing mAbs directed against either IL-23p19 or
IL-12/23p40, or they were treated with isotype control Abs.
Skin disease progressed in a similar manner in isotype control
Ab-treated (Figures 3a and 4a), anti-IL-23p19 mAb-treated
(Figures 3b and 4a), and anti-IL-12/23p40 mAb-treated
(Figures 3c and 4a) K5.hTGF-b1 transgenic mice. It is
noteworthy that all histological analyses of lesional skin
isolated from K5.hTGF-b1 transgenic mice undergoing
treatment were similar, and showed hyperkeratosis with
serum crust, acanthosis, and a superficial mixed inflamma-
tory infiltrate consisting of mononuclear cells and scattered
eosinophils (Figure 3). Weight loss was similar across all
groups tested (Figure 4b). To ensure that mAbs were
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functional in neutralizing IL-12 and IL-23, treatment with
1mg of anti-IL-23p19 and anti-IL-12/23p40 mAbs prevented
the onset of experimental autoimmune encephalomyelitis
(Figure 4c), a disease mediated by IL-23 and Th17 cells (Chen
et al., 2006).
DISCUSSION
The results presented here indicate that the IL-23/Th17
inflammatory pathway is not responsible for maintenance of
inflammatory skin disease in K5.hTGF-b1 transgenic mice. As
TGF-b1 is a critical component in the development of Th17
cells in mice (Bettelli et al., 2006; Mangan et al., 2006;
Veldhoen et al., 2006), we originally hypothesized that
overexpression of TGF-b1 by keratinocytes could influence
the differentiation of naive T cells in skin-draining lymph
nodes, and lead to enhanced development of Th17 cells.
These Th17 cells, through expression of skin-homing
receptors, CCR6 and CCR4 (Acosta-Rodriguez et al.,
2007a, b), would return to the skin and release inflammatory
cytokines, such as IL-17A, IL-22, and TNF-a. The net result
would be the establishment and maintenance of psoriasiform
lesions (Li et al., 2004). Disease would resolve on mAb
therapy directed against IL-23, similar to human psoriasis
(Krueger et al., 2007; Kimball et al., 2008; Leonardi et al.,
2008; Papp et al., 2008). We showed, however, that levels of
IL-23 and Th17 cytokines are not elevated in K5.hTGF-b1
transgenic mice (Figures 1 and 2). We also showed that mAb
targeting of the IL-23/Th17 inflammatory pathway does
not affect the maintenance of skin disease in these mice
(Figures 3 and 4). As we learn more about the role of IL-23
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Figure 1. mRNA levels of IL-23/Th17 pathway cytokines are not elevated in lesional skin of K5.hTGF-b1 transgenic mice. Total RNA was isolated from the skin
of WT mice (n¼ 4), and from the lesional (n¼7) and non-lesional (n¼ 4) skin of K5.hTGF-b1 transgenic mice, and cDNA was synthesized as detailed in the
Materials and Methods section. Data are presented as fold change (left column) or relative difference with 95% confidence interval for (a) lesional skin compared
with WT skin, (b) non-lesional skin compared with WT skin, and (c) lesional skin compared with non-lesional skin. *Po0.05 using a two-tailed t-test, with four
to nine degrees of freedom and 95% confidence intervals for graphing.
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and Th17 cells in the pathogenesis of human psoriasis and
other inflammatory skin diseases, it will be critical to
investigate this pathway in each of the various murine
models of these diseases. We believe that this study will
provide the framework to carry out these future studies.
There are some limitations to our study. The K5.hTGF-b1
transgenic mice showed clinical, histological, and cytokine
expression features that were different than those originally
described by Li et al. (2004). More specifically, this original
publication described many characteristics of human psor-
iasis, yet our findings suggest that these mice have features
that resemble human atopic dermatitis more so than human
psoriasis (for example, crusted skin lesions, scattered tissue
eosinophils, high lesional IL-4 expression, and high-serum IgE
levels). It is unclear why we found such different results
compared with the results arrived at by Li et al., but this may
be because of changes in transgene expression that could
occur after years of breeding of K5.hTGF-b1 transgenic mice.
Although we have definitively shown that the IL-23/Th17
inflammatory pathway is not involved in the inflammatory
skin disease observed in these transgenic mice, the precise
mechanisms underlying pathogenesis in these mice remain
unresolved. For example, the contributions of bacterial
colonization and scratching in exacerbating skin lesions in
these mice may be studied further, and would be particularly
relevant in further understanding the pathogenesis of atopic
dermatitis.
TGF-b1 expression can paradoxically activate and sup-
press the immune function (Wan and Flavell, 2007).
Although the combination of TGF-b1 and IL-6 can direct
the differentiation of murine Th17 cells, TGF-b1 can also
inhibit the pathogenic function of these cells, even in the
presence of IL-23 (McGeachy et al., 2007). It is possible that
TGF-b1, in the setting of K5.hTGF-b1 transgenic mice, does
not drive Th17 cells toward an inflammatory phenotype, but
restricts their pro-inflammatory activities. Furthermore,
TGF-b1, in a non-inflammatory tissue milieu, can induce
Treg differentiation from naive T cells as well as the
production of the Treg transcription factor, foxp3 (McGeachy
and Cua, 2008). Our data indicate that mRNA levels of
Treg-associated factors, foxp3, IL-12/35p35, and IL-10,
are elevated in lesional skin than in non-lesional skin. It is
also noteworthy that the protein subunit encoded by IL-12/
35p35 can bind with the Epstein–Barr virus-induced 3
protein, or EBI3, to create the anti-inflammatory Treg-
associated cytokine known as IL-35 (Collison et al., 2007).
Although foxp3, IL-12/35p35, and IL-10 mRNA are elevated
in skin of K5.hTGF-b1 transgenic mice, it is still not known
whether Treg populations play a key pathogenic role in
these mice.
TGF-b1 has an unclear role in the pathogenesis of human
psoriasis. In one study of 60 patients with psoriasis and 38
without psoriasis, serum TGF-b1 was increased in psoriatics
than in controls, and higher TGF-b1 correlated with higher
clinical disease scores (Nockowski et al., 2004). Another
study showed a correlation of disease severity with concen-
trations of TGF-b1 in psoriatic scales (Flisiak et al., 2002).
Several other studies, however, have shown a negative or
absent correlation of expression of TGF-b1 or its receptors in
psoriasis (Leivo et al., 1998; Doi et al., 2003). These
published studies are insufficient to determine definitely
whether there is a positive or negative correlation between
TGF-b1 and psoriasis. Indeed, recent studies showed that
TGF-b1 is not involved in the differentiation of human Th17
cells (unlike in the development of murine Th17 cells)
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Figure 2. IL-23/Th17 cytokine protein levels are not detectable in lesional
skin of K5.hTGF-b1 transgenic mice. Total protein was isolated from the skin
of WT mice (n¼ 3), and from the lesional (n¼ 4–8) and non-lesional (n¼7–8)
skin of K5.hTGF-b1 transgenic mice. Protein was assayed by ELISA. (a) human
TGF-b1; (b) IFN-g; (c) IL-4; (d) serum IgE; (e) IL-23p19/p40; (f) IL-12/23p40; (g)
IL-17A; and (h) IL-22. (a–c and e–h) *Po0.05 comparing WT with transgenic
samples using a one-way analysis of variance with Tukey’s post test. (d)
*Po0.0005 comparing WT with transgenic serum using an unpaired t-test.
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(Acosta-Rodriguez et al., 2007a, b), and that there is no
association between TGF-b1 polymorphisms and psoriasis
susceptibility (Baran et al., 2007). Taken together, our current
study, as well as these recent studies in humans, suggests that
TGF-b1 does not play a major role in the pathogenesis of
psoriasis.
MATERIALS AND METHODS
Animals
All breeding and experiments were undertaken with review and
approval from the Portland Veterans Affairs Medical Center
Institutional Animal Care and Use Committee. K5.TGF-b1 transgenic
mice were a kind gift from Dr Xiao-Jing Wang, University of
Colorado (Li et al., 2004). C57BL/6 mice were purchased from
Jackson Laboratories (Bar Harbor, ME). To ensure the proper genetic
identification of mice, DNA was isolated from tails of mice at 3
weeks of age using a DNeasy Blood and Tissue Kit (Qiagen,
Valencia, CA), according to the manufacturer’s instructions.
PuReTaq Ready-To-Go PCR beads (GE Healthcare, Piscataway, NJ)
were used for DNA amplification, following the manufacturer’s
instructions. Primer sequences and product sizes were as follows:
K5.hTGF-b1 forward, 50-GCGTCTGCTGAGGCTCAAGTT-30 and
reverse 50-ACCTCGGCGGCCGGTAG-30, 271 bp. The annealing
temperature for K5.hTGFb1 primers was 541C.
Scoring of inflammatory skin disease
All mice were monitored from birth to determine the extent, if
any, of skin or systemic disease. K5.hTGF-b1 transgenic mice
developed a visible skin disease between 2 and 4 months of age,
with disease being somewhat variable among individual animals.
A skin-scoring system was instituted to standardize all experiments
involving cytokine levels, treatment of established disease, and
genetic crosses. Scores were assessed as follows: 0.5¼ altered
hair growth; 1¼ thinning of ventral and dorsal hair and mild scaling
on the upper back; 2¼o50% areas with hair loss, widespread
scaling, and Koebner’s phenomenon near ear tags; 3X50% areas
with hair loss and erythematous scaly plaques; and 4X50% areas
with hair loss, erythematous scaly plaques, retracted eyelids,
and dehydration. All animals that were used for measurement of
cytokine levels were between 4 and 6 months of age. The mice
were euthanized at the end of the experiments by CO2, on 410%
weight loss, or if showing obvious dehydration. The mice were
housed in specific pathogen-free facilities and given food and water
ad libitum.
Isotype Ab
week 0
week 3
week 3
(lo)
week 3
(hi)
Anti-IL-23p19 Anti-IL-12/23p40
Figure 3. Treatment with neutralizing antibodies directed against IL-23 subunits, IL-23p19, or IL-12/23p40, does not improve established inflammatory skin
disease in K5.hTGF-b1 transgenic mice. K5.hTGF-b1 transgenic mice were treated on weeks 0, 1, and 2 with 1mg isotype control Ab (a), anti-IL-23p19 mAbs
(b), or anti-IL-12/23p40 mAbs (c). n¼ 5 mice per group for anti-IL-23p19 and anti-IL-12/23p40, and n¼ 4 mice per group for isotype. (a–c) Representative
clinical photos are shown before (week 0) and after treatment (week 3), whereas representative H&E skin sections are shown after treatment at week 3. It is
interesting to note that all histological analyses of lesional skin isolated from K5.hTGF-b1 transgenic mice undergoing treatment were similar, and showed
hyperkeratosis with serum crust, acanthosis, and a superficial mixed inflammatory infiltrate consisting of mononuclear cells and scattered eosinophils.
Bar¼40 mm in figures labeled ‘‘lo’’ and 20mm in figures labeled ‘‘hi.’’
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RNA isolation and qRT-PCR
Clinically abnormal (that is, lesional) and clinically normal (that is,
non-lesional) skins were obtained from C57BL/6 and K5.hTGF-b1
transgenic mice, snap frozen in liquid nitrogen, placed into Trizol
(Sigma, St louis, MO), and homogenized with a mechanical rotor for
30 seconds. RNA was isolated according to standard Trizol protocol,
and was followed by further purification using an RNeasy kit
(Qiagen). cDNA was prepared from 1 mg of total RNA by reverse
transcription using iScript (Bio-Rad, Hercules, CA). Five reactions
were pooled and diluted 5 times with water to establish the same
pool of cDNA for all qRT-PCR experiments. qRT-PCR was performed
with TaqMan primers and fluorescent probes for GAPDH, hTGF-b1,
IL-23p19, IL-12/23p40, IL-12/35p35, IL-23R, IL-6, IL-17A, IL-22,
IFN-g, RORgt, CCR6, IL-4, foxp3, and IL-10 (Applied Biosystems,
Carlsbad, CA) on the MyiQ system (Bio-Rad). Relative quantification
by the delta–delta Ct method was carried out in Excel, using GAPDH
as the housekeeping gene. To generate logarithmic graphs, 100 was
added to all observations and the log of each was calculated. WT
results were fixed at two (log 100). Gains relative to WT were shown
as greater than two and losses were shown as less than two.
Protein isolation and ELISA
Sera, lesional skin, and non-lesional skin were obtained from C57BL/
6 and K5.hTGF-b1 transgenic mice. Skin was snap frozen in liquid
nitrogen, pulverized when immersed in liquid nitrogen, and
subsequently re-suspended in a protein lysis buffer (10mM Tris-
HCl, pH 7.5; 0.5mM EDTA-Na2; 0.5mM EGTA; 1% Triton X-100;
0.5mM PMSF; and Protease Inhibitor Mix, diluted from 100 stock
(Sigma)). The samples underwent three freeze–thaw cycles and were
spun at full speed for 15minutes to fractionate the sample and
remove protein. Human TGF-b1 and murine IL-17A, IL-22, IL-1a,
TGF-b1, and IL-12/23p40 ELISA kits (R&D Systems, Minneapolis,
MN), the IL-23 p19/p40, IFN-g, and IL-4 ELISA kits (eBiosciences,
San Diego, CA), and the IgE ELISA kit (Biolegend, San Diego, CA)
were used according to the manufacturer’s instructions.
Cell culture
Lymph nodes from WT, K5.hTGF-b1 transgenic, or IL-17A knockout
mice were harvested and cultured for 3 days in RPMI-1640, 5% FBS,
2mM L-glutamine, and 100Uml1 penicillin/100 mgml1 strepto-
mycin. Cells were cultured alone or in the presence of IL-17-
promoting cytokines or antibodies, including hTGF-b1, IL-6,
anti-IFN-g, and recombinant murine IL-23 (Li et al., 2007). The
cells were plated at a density of 5 106 cells per ml in six-well
plates. Then, 150 ml aliquots of cell culture supernatant, to use as
protein assay controls, were taken at 24-hour intervals, beginning at
12 hours. The culture medium was supplemented with 1ml new
medium on day 3.
Treating established inflammatory skin disease in K5.hTGF-b1
transgenic mice
Neutralizing mAbs directed against murine IL-23p19 (CNTO 6163)
and IL-12/23p40 (CNTO 3913), as well as murine IgG isotype
control antibody (CNTO 1322), were obtained from Centocor R&D
(Radnor, PA). Generation and in vitro and in vivo characterization
CNTO 3913 and CNTO 1322 have been described elsewhere (Held
et al., 2008). CNTO 6163 is a rat (v)/mouse(c) IgG2ak chimeric
antibody developed by Centocor using variable regions from the
neutralizing rat anti-mouse IL-23p19 antibody, CNTO 209. Func-
tional variable region genes were identified from the hybridoma cell
line and the heavy-chain and light-chain variable-region genes were
cloned into murine IgG2a and Kappa expression vectors, respec-
tively. Both single-gene vectors were combined into a single double-
gene vector, which was transfected into GS-CHO cells to generate a
stable cell line expressing the CNTO 6163 antibody.
A concentration of 1mg of mAb per animal was used. The
animals were paired by disease score and birth month and placed
into the anti-IL-23p19, anti-IL-12/IL-23p40, or isotype control Ab
treatment groups. Intraperitoneal (i.p.) injections were given once
weekly for 3 weeks. Weight changes were monitored weekly, and
clinical skin disease was scored between days 0 and 21. The animals
were killed on day 21, and lesional and non-lesional skin samples
were prepared for routine histology.
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Figure 4. Skin disease score and weight do not improve after treatment of
K5.hTGF-b1 transgenic mice with neutralizing antibodies directed against
IL-23 subunits, IL-23p19, or IL-12/23p40. (a) Severity of disease was assessed
at weeks 0 and 3. (b) Weights of mice were assessed at weeks 0 and 3, as an
additional quantitative measurement of disease. (c) Anti-IL-23p19 and anti-IL-
12/23p40 mAbs were effective in preventing experimental autoimmune
encephalomyelitis in SJL mice. Mice were injected i.p. on days 1 and 6 with
1mg of anti-IL-23p19 or anti-IL-12/23p40 mAbs, or isotype IgG Abs, or
nothing. Disease severity was measured daily after immunization with
PLP139-151.
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Treating experimental autoimmune encephalomyelitis
Female SJL mice (8–12 weeks old) were immunized subcutaneously
with PLP139-151 peptide (Genscript, Piscataway, NJ) emulsified in
CFA, supplemented with 2mgml1 Mycobacterium tuberculosis
(Difco, San Jose, CA). The mice (n¼ 3 per group) were injected i.p.
with 1mg anti-IL-23p19 mAb, anti-IL-12/23p40 mAb, or isotype
control IgG at days 1 and 6. Clinical disease was assessed daily
using a scoring system as follows: 0¼ normal; 0.5¼ limp tail;
1¼ hind limb weakness; 1.5¼ inability to right>; 2¼walks with
difficulty; 2.5¼ hind limb paresis; 3¼ complete hind limb paralysis;
3.5¼ hind limb paralysis with front limb weakness; 4¼ hind limb
paralysis with front limb paresis; and 5¼moribund/death. Disease
was scored daily until day 15.
Statistical analyses
Statistical analyses for qRT-PCR results were carried out using a two-
tailed t-test, with four to nine degrees of freedom and 95%
confidence intervals for graphing. Statistical analyses for protein
results comparing WT with transgenic samples were carried
out using a one-way analysis of variance with Tukey’s post test,
except for the serum IgE results, which were compared using an
unpaired t-test.
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